KAPA · Kairos Pharma Ltd
United States · RS rating 41 · As of 2026-11-03
| Price | 0.51 USD |
|---|---|
| 1-day change | +6.5% |
| RS rating (overall / 1M / 3M / 12M) | 41 / 2 / 95 / 19 |
| Stage | Declining |
| Composite / Minervini / CANSLIM score | 29 / 25 / 40 |
| Industry group (rank) | Medical-Biomed/Biotech (154) |
| EPS growth Q/Q | +25.0% |
| Sales growth Q/Q | – |
| Distance from 52-week high | +72.7% |
| Market cap (USD) | $14.3M |